Abstract: Shipping system for temperature-sensitive materials. In one embodiment, the shipping system includes a frame defining an enclosure. The frame includes a bottom, a top, a front, a rear, a left side, a right side, a left corner gusset, and a right corner gusset. The front serves as a door. Thermal breaks are provided in one or more of the bottom, the front, the left corner gusset, and the right corner gusset. Vacuum insulated panels are positioned along all sides of the frame. Many of the vacuum insulated panels are encapsulated between the frame and an outer shell. A plurality of phase-change material assemblies are positioned within the frame along all sides. Heat-spreaders are positioned interior to the phase-change material assemblies. The shipping system are dimensioned so that four such shipping systems are seated on a prorate manual cargo sheet.

Abstract: Method and system are designed for storing and/or transporting temperature-sensitive materials. The system is designed to keep a payload within a desired temperature range of +2° C. to +8° C. for an extended time in a warm ambient environment. The system includes a thermally insulated container and first and second phase-change materials, each of the phase-change materials having a different solid/liquid phase-change temperature. Both phase-change materials are preconditioned to a solid state for pack-out. The first phase-change material has a solid/liquid phase-change temperature that is within the desired temperature range and that is at or below a hibernation temperature of about +5° C. to +6° C. The second phase-change material has a solid/liquid phase-change temperature that is above the hibernation temperature.

Abstract: Methods for treating a cancer (such as, e.g., acute myeloid leukemia) comprising administering to a subject (such as, e.g., a subject who has acquired resistance to a therapy comprising at least one antineoplastic agent and/or at least one hypomethylating agent) at least one E-selectin antagonist, wherein the subject is further administered at least one antineoplastic agent (such as, e.g., venetoclax) and/or at least one hypomethylating agent are disclosed.

Abstract: Methods for treating a cancer (such as, e.g., acute myeloid leukemia) comprising administering to a subject (such as, e.g., a subject who has acquired resistance to a therapy comprising at least one antineoplastic agent and/or at least one hypomethylating agent) at least one E-selectin antagonist, wherein the subject is further administered at least one antineoplastic agent (such as, e.g., venetoclax) and/or at least one hypomethylating agent are disclosed.

Abstract: Method and system for storing and/or transporting temperature-sensitive materials. In one embodiment, the system is designed to keep a payload within a desired temperature range of +2° C. to +8° C. for an extended time in a warm ambient environment. The system includes a thermally insulated container and first and second phase-change materials, each of the phase-change materials having a different solid/liquid phase-change temperature. Both phase-change materials are preconditioned to a solid state for pack-out. The first phase-change material has a solid/liquid phase-change temperature that is within the desired temperature range and that is at or below a hibernation temperature of about +5° C. to +6° C. The second phase-change material has a solid/liquid phase-change temperature that is above the hibernation temperature.

Abstract: Shipping system for temperature-sensitive materials. In one embodiment, the shipping system may include a frame defining an enclosure. The frame may include a bottom, a top, a front, a rear, a left side, a right side, a left corner gusset, and a right corner gusset. The front may serve as a door. Thermal breaks may be provided in one or more of the bottom, the front, the left corner gusset, and the right corner gusset. Vacuum insulated panels may be positioned along all sides of the frame. Many of the vacuum insulated panels may be encapsulated between the frame and an outer shell. A plurality of phase-change material assemblies may be positioned within the frame along all sides. Heat-spreaders may be positioned interior to the phase-change material assemblies. The shipping system may be dimensioned so that four such shipping systems may be seated on a prorate manual cargo sheet.

Abstract: The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.

Abstract: Cortical entrainment device (CED) and associated methods are provided. The CED device includes an electroencephalographic (EEG) analysis module configured to receive and process an EEG waveform for analyzing brain activity of a patient with epilepsy or a seizure disorder; an interictal epileptiform discharge (IED) analysis module configured to receive and process an IED waveform for analyzing the brain activity of the patient; and a diagnostic module that is configured to interface with the EEG analysis module and the IED analysis module, to evaluate spectral and temporal waveform characteristics, and to provide instructions to a therapy module for providing a stimulus for the patient based on the analysis by the EEG analysis module and the IED analysis module.

Abstract: The invention is directed to methods of treating patients suffering from Peyronie's disease, methods of identifying patients suffering from Peyronie's disease and a computer program for identifying patients suffering from Peyronie's disease.

Abstract: Provided are adenoviral vectors and the production of such vectors. In particular, fiber shaft modifications for efficient targeting of adenoviral vectors are provided. The fiber shaft modifications can be combined with other modifications, such as fiber knob and/or penton modifications, to produce fully ablated (detargeted) adenoviral vectors. A scale-up method for the propagation of detargeted adenoviral vectors is also provided.

Abstract: Provided are adenoviral vectors and the production of such vectors. In particular, fiber shaft modifications for efficient targeting of adenoviral vectors are provided. The fiber shaft modifications can be combined with other modifications, such as fiber knob and/or penton modifications, to produce fully ablated (detargeted) adenoviral vectors. A scale-up method for the propagation of detargeted adenoviral vectors is also provided.

Abstract: An adenoviral vector including at least one DNA sequence encoding a clotting factor, such as, for example, Factor VIII, or Factor IX. Such vectors may be administered to a host in an amount effective to treat hemophilia in the host. The vectors infect hepatocytes very efficiently, whereby the hepatocytes express the DNA sequence encoding the clotting factor.

Abstract: This invention relates to mutated adenoviral fiber proteins and adenovirus particles containing such proteins. It further relates to polynucleotides encoding the proteins and vectors containing polynucleotides. It also relates to methods for making and using the adenoviral particles. With the mutated fiber proteins, the adenovirus particles no longer bind to their natural cellular receptor. They can then be “retargeted” to a specific cell type through the addition of a ligand to the virus capsid, which causes the virus to bind to and infect such cell. Specific fiber mutations are listed, which ablate binding to the natural receptor. Adenovirus particles with certain fiber mutations were found to enhance gene transfer to and expression in liver as compared to viral particles with wild-type fiber.

Abstract: The present invention relates to targeting molecules which are useful to specifically target an adenoviral particle to a desired cell type. These targeting molecules comprise a soluble adenoviral receptor domain, a trimerization domain, and a targeting ligand domain. Further provided are polynucleotides encoding such targeting molecule, expression vectors including such polynucleotides, and methods to target an adenoviral particle to a cell, as well as methods to deliver a heterologous gene selectively to a cell.

Abstract: An adenoviral vector including at least one DNA sequence encoding a clotting factor, such as, for example, Factor VIII, or Factor IX. Such vectors may be administered to a host in an amount effective to treat hemophilia in the host. The vectors infect hepatocytes very efficiently, whereby the hepatocytes express the DNA sequence encoding the clotting factor.

Abstract: An adenoviral vector including at least one DNA sequence encoding a clotting factor, such as, for example, Factor VIII, or Factor IX. Such vectors may be administered to a host in an amount effective to treat hemophilia in the host. The vectors infect hepatocytes very efficiently, whereby the hepatocytes express the DNA sequence encoding the clotting factor.

Abstract: Alkali metal carboxylate salts of starch-polyacrylonitrile graft copolymers produced by saponifying a starch-polyacrylonitrile graft copolymer are improved significantly by employment of step-wise grafting of the acrylonitrile, and by employment of starch which has been treated by one or more of the following steps, thinning, defatting, precooking.

Abstract: An information storage device (10) includes a cartridge (14) removably inserted into a cradle (13) that has a drive module (18) releasably coupled to an interface module (17). The interface module can be operatively coupled by a cable (12) to a remote system. Communications through the cable conform to an industry-standard protocol. The storage device can receive power from either the cable or an external power source (31). The interface module can detect a change in the source of its operating power during normal system operation, and ensure that this is reported through the cable.